Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Esketamine for Pediatric MDD with Suicidal Ideation
NCT03185819Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2017
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of esketamine in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started Oct 2017; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03185819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03185819.